To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Matthew Tontonoz
The same properties that make certain cancers hard to treat may also promote their death by ferroptosis, scientists at the Sloan Kettering Institute have found.
Emily Ward
A seven-year mesothelioma survivor encourages patients with cancer to be their own advocate.
Katie Kosko
A phase 3 trial compared Keytruda versus chemotherapy for patients with advanced pretreated malignant pleural mesothelioma.
Katie Kosko
Cediranib combined with platinum-based chemotherapy helped patients live longer than placebo.
Kristie L. Kahl
A registered dietician discussed the importance of maintaining one’s weight while going through treatment for mesothelioma.
Kristie L. Kahl
CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.
Kristie L. Kahl
CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors. 
Kristie L. Kahl
Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.
Matthew Tontonoz
Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.
Kristie L. Kahl
Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

Sign In

Not a member? Sign up now!
Continue without login